Strong Q1 driven by wealth management and banking MLP released a strong set of Q1 results in line with expectations and at new record levels. In detail: Sales increased by a solid 8% yoy to € 284m (eNuW: 280m), slightly above estimates. The main drivers were the strong banking business (Interest Income +89% yoy to € 22m) and Wealth  [ … ]

Strong Q1: First positive group EBITDA as prod. portfolio scales Topic: Q1 clearly underpins MPCES' operational progress (ramp-up of production portfolio) and successful cost cutting program. At the same time, it remains highly attractive with shares trading on a ~65% discount to the NAV of the company's assets. Q1 sales grew by 51% yoy to $ [ … ]

Healthy Q1 results // FY24 guidance confirmed Healthy Q1 results underpin that Westwing was able to continue the trend of yoy GMV growth witnessed in recent quarters. Q1 sales increased by 6% yoy to € 109m (eNuW: € 107.7m), showing an acceleration of growth versus Q4 (+2% yoy), driven by growth in active customers (+2% yoy to 1.28m) a [ … ]

FY'24e to see improvements in top and bottom-line Topic: LAIQON recently released mixed final Q4 results. Moreover, the outlook of performance fees for FY24e, poses LAIQON for another year of solid top-line growth and profitability improvements. Final results in line: LAIQON released sales and EBITDA prelims in February and both final figures [ … ]

High single-digit €m order confirms growth prospects Nynomic’s subsidiary m-u-t GmbH has received a high single-digit order, which should translate into sales over the course of FY24/25e. Most importantly, this coupled with the recently announced product launch of the LabScanner Plus, a bulk-testing tool for pharmaceutical companies, [ … ]

Final FY23 as expected, solid start into FY24 2023 figures inline with prelims. To recap: FY23 sales decreased by 8.5% yoy to € 200m, largely driven by the highly cyclical Specialty Alumina segment, which reported sales of € 57.8m (-18.5% yoy). On the contrary, Functional Fillers’ sales decreased by only 3.9% to € 142.3m, a [ … ]

Continued strong growth in Q3; chg. Topic: Cantourage reported preliminary Q3 figures with significant sales growth and notable EBITDA improvements. The planned abolishment of the narcotic drug status of medical cannabis in Q1 2024e should further drive patient numbers and sales growth going forward. Q3 sales grew by 79% yoy to € 6.1m (9 [ … ]